Scientists Gloomy Over Outlook For Research Funding
ARLINGTON, Va., April 10, 2017 /PRNewswire/ -- A global survey of life scientists reveals a high level of uncertainty regarding the outlook for research funding. According to a new report from BioInformatics LLC, university scientists in the US, Europe and Asia anticipate little growth in their budgets in FY2017. Scientists employed by pharmaceutical and biotechnology companies project modest but steady growth in their budgets with the greatest increases expected in Asia.
Lab Budgets and Sources of Funding in 2017: The Market Outlook for the United States, Europe and Asia is the latest report from BioInformatics LLC. The report is based on a survey of more than 1,000 life scientists who answered a detailed questionnaire about their budget and spending plans for 2017. Suppliers of laboratory instrumentation and consumables rely upon the biennial report to project demand in ten broad product categories.
"Scientists in the US and Europe are the most pessimistic about their future," said Madelaine Denno, Ph.D., a senior analyst at BioInformatics LLC. "This is such an exciting time to be in life science research, but there's a real sense of frustration at many labs. Even though US budgets on average remain much higher than those in Asia, it's Asian scientists who are most optimistic about their future prospects for funding."
The report contains detailed information on current and projected funding, planned spending on instrumentation and consumables, and scientists' opinions on funding and the future of life science research. A complimentary Executive Summary is now available on the BioInformatics website.
ABOUT BIOINFORMATICS LLC
BioInformatics LLC and its SDi division together form the premier research and advisory firm serving senior executives at companies making the tools of science. By leveraging our expert network of more than 75,000 scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Offerings include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
For more information contact:
Madeline Kalicka
BioInformatics LLC
2111 Wilson Boulevard
Suite 250
Arlington, VA 22201
Phone: 310.641.4982
[email protected]
www.gene2drug.com
SOURCE BioInformatics LLC
Share this article